Michael P McLane
Overview
Explore the profile of Michael P McLane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziegelmann M, Hu Y, Xiang Q, Liu G, McLane M, Trost L
Urology
. 2023 Mar;
175:126-131.
PMID: 36863600
Objective: To evaluate cumulative and incremental changes in penile curvature after each treatment cycle of collagenase clostridium histolyticum (CCH) in men with Peyronie's disease (PD). Methods: Data from 2 phase...
2.
Bass L, Kaufman-Janette J, Joseph J, Kaminer M, Clark J, Fabi S, et al.
Plast Reconstr Surg Glob Open
. 2022 Jun;
10(5):e4306.
PMID: 35646496
Background: Collagen-rich fibrous septae and subcutaneous adipose protrusions play a role in cellulite pathophysiology. Collagenase clostridium histolyticum-aaes (CCH-aaes) injection causes enzymatic release of septae to resolve cellulite depressions and create...
3.
Kaufman-Janette J, Joseph J, Kaminer M, Clark J, Fabi S, Gold M, et al.
Dermatol Surg
. 2021 Apr;
47(5):649-656.
PMID: 33840781
Background: Fibrous septae play a role in contour alterations associated with cellulite. Objective: To assess collagenase clostridium histolyticum-aaes (CCH) for the treatment of cellulite. Materials And Methods: Two identically designed...
4.
Wolfe H, Rosenberg E, Ciftci K, Edgecombe J, McLane M
J Cosmet Dermatol
. 2021 Mar;
20(6):1643-1647.
PMID: 33735499
Background: Collagenase clostridium histolyticum (CCH-aesthetic formulation [CCH-aaes]; QWO™ [Endo Aesthetics, Malvern PA, USA] is approved as a subcutaneous injection for treatment of cellulite. In the aesthetic practice, dilution of marketed...
5.
Kaufman-Janette J, Bass L, Xiang Q, McLane M, Kirby M, Vijayan S
Plast Reconstr Surg Glob Open
. 2021 Jan;
8(12):e3316.
PMID: 33425621
Methods: After RCT unblinding, women could enroll in OLE for assessment of long-term CCH durability (observation only, up to day 720) or CCH treatment/retreatment, the latter in women with moderate-to-severe...
6.
Bhatia A, McLane M, Priestley T, Vijayan S, Gelbard M
J Drugs Dermatol
. 2020 Oct;
19(9):852-856.
PMID: 33026751
Background: Clostridium collagenase histolyticum (CCH) is being evaluated in women as a cellulite treatment. Objective: To report preclinical safety and human pharmacokinetics (PK) and safety data for CCH. Methods: Across...
7.
Cohen J, Sadick N, Kirby M, McLane M, Lenderking W, Bender R, et al.
Dermatol Surg
. 2020 Oct;
46(12):1628-1635.
PMID: 33009069
Background: The Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported PCSS (PR-PCSS) are newly developed tools for assessing cellulite severity. Objective: To report on the reliability, validity, and...
8.
Goldstein I, McLane M, Xiang Q, Wolfe H, Hu Y, Gelbard M
Urology
. 2020 Sep;
146:145-151.
PMID: 32896582
Objective: To examine the long-term (5-year) efficacy and safety of collagenase clostridium histolyticum (CCH) therapy in men with Peyronie's disease and varying degrees of plaque calcification. Materials And Methods: CCH-treated...
9.
Sadick N, Goldman M, Liu G, Shusterman N, McLane M, Hurley D, et al.
Dermatol Surg
. 2019 Mar;
45(8):1047-1056.
PMID: 30829779
Background: Edematous fibrosclerotic panniculopathy (EFP; cellulite) is associated with thickening and contraction of collagen-rich subdermal septae. Collagenase clostridium histolyticum (CCH) may disrupt collagen-rich septae. Objective: To evaluate the safety and...
10.
Roitman M, Wescott S, Cone J, McLane M, Wolfe H
Pharmacol Biochem Behav
. 2010 May;
97(1):138-43.
PMID: 20478327
Many therapies designed to reduce food intake and body weight act, in part, by blocking the dopamine transporter (DAT) - a protein responsible for clearing extracellular dopamine (DA) after release...